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Abstract 
A 72-year-old female and a 57-year-old male with chronic hepatitis C were treated with a 
combination therapy of pegylated interferon (PEG-IFN)-α 2a (180 μg s.c. once a week) 
and ribavirin (1,000 mg orally daily). This resulted in the destruction of melanocytes at 
the injection site in both patients. In the male patient, the depigmentation progressed to 
the surrounding skin area. The dermatologist concurred with vitiligo as the diagnosis in 
both patients. Injection and surrounding site vitiligo associated with PEG-IFN-α 2b 
treatment for hepatitis C was noticed in previous case studies. For the first time, the case 
reports below highlight the same immunological adverse event secondary to PEG IFN-α 
2a/ribavirin combination therapy and explain, in part, the complex interaction between 
host immune response and viral genotype. In addition, we systematically review 
drug-induced vitiligo and autoimmune diseases associated with the depigmentation 
disorder. 
 
Introduction 
Hepatitis C virus (HCV) is second only to non-alcoholic steatohepatitis (NASH) as the 
most common cause of chronic hepatitis [1]. Since 2001, the most widely accepted viral 
clearance therapy is pegylated interferon (PEG-IFN)-α 2b/2a in combination with 
ribavirin. Adverse effects of this combination therapy are variable and mainly include 
flu-like illness, neuropsychiatric symptoms such as depression, and thyroid, 
dermatological and hematological abnormalities. Existing literature attributes all major 
side effects of the combination therapy to PEG-IFN except hemolytic anemia, which is a 
side effect of ribavirin [2]. Patients should be monitored for further evaluation of 
additional adverse effects of PEG-IFN.  
Case Rep Dermatol 2010;2:156–164 
DOI: 10.1159/000320207 
Published online: 
August 27, 2010 
© 2010 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
157
Few cases of interferon-associated vitiligo have been reported in the past [3–8]. 
Vitiligo, an idiopathic acquired form of skin disease, is caused by destruction of epidermal 
melanocytes. The worldwide prevalence is 1–2%, with no race or gender predilection. The 
presence of serum autoantibodies targeting the surface of melanocytes [9] and of a large 
number of T cells specific for melanocyte antigens in vitiligenous lesions [10] suggests an 
autoimmune etiology; however, the exact pathogenesis remains unclear. PEG-IFN-α 2b 
injection site vitiligo has been reported once [8]. However, PEG-IFN-α 2a injection site 
and surrounding site vitiligo has never been reported; the following case reports highlight 
this potential treatment-related complication. 
Case Presentation 
Case 1 
A 72-year-old Hispanic female was referred for chronic hepatitis C evaluation. Physical examination 
was normal. She denied any exposure to hepatitis-C-related risk factors. Her laboratory workup was 
negative except for raised liver enzymes, viral load log 5.5, and genotype 1a. She was started on 
combination therapy of PEG-IFN-α 2a (Pegasys; Roche Pharmaceuticals, Nutley, N.J., USA) 180 μg 
once a week and ribavirin 1,000 mg daily. Apart from flu-like symptoms after the first few injections, 
she tolerated the combination therapy well. After 12 weeks of therapy, her HCV RNA was undetectable. 
During the fourth month of therapy, the patient developed white macular skin lesions around 
PEG-IFN-α 2a injection sites on both upper arms (fig. 1a, b). These lesions increased in diameter during 
therapy and remained the same after discontinuation of therapy. Her HCV RNA (PCR) was 
undetectable after 48 weeks of treatment, but after 6 months, it returned positive. 
Case 2 
A 57-year-old Hispanic male was referred (to an internist) for complete workup for hepatitis C. He 
denied any exposure to hepatitis-C-related risk factors. He had abnormal liver enzyme values, but other 
laboratory values were within normal limits. His hepatitis C workup showed genotype 2b and viral load 
log 7. He was started on PEG-IFN-α 2a 180 μg weekly and ribavirin 800 mg daily. In the fifth month of 
therapy, he developed white macular lesions on both thighs around PEG-IFN-α 2a injection sites (fig. 
2). The vitiligo spread throughout the whole body except his face. His HCV RNA was undetectable after 
12- and 24-week intervals of therapy, and 6 months after discontinuation of therapy. 
Both patients agreed to continue with the antiviral treatment. There was no past medical or family 
history of any autoimmune disorder or especially vitiligo. Autoimmune markers were also negative in 
both patients. Diagnosis of vitiligo has been confirmed by dermatologist consultation in both cases 
(table 1). 
Discussion 
Understanding the immunological adverse events in chronic hepatitis C is a complex 
phenomenon. The genotypic variability of the treatment response and host 
immunological status plays an important role in this complexity [11]. It was observed in 
the previous case reports that autoimmune manifestations are more common in patients 
with stronger immune response. Th1 and Th2 cytokine ratio may be a major determinant 
affecting the outcome of the treatment. The Th2 cytokine profile (IL-4 and IL-10) 
correlates with the persistence of the disease [12] and less autoimmune manifestations.  
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Vitiligo and Interferon 
We reviewed all case reports of vitiligo in hepatitis C patients and realized that vitiligo 
lesions appeared during the first 6 months of IFN-α or PEG-IFN-α therapy. In a US male 
veterans’ study, a significant relationship between hepatitis C and vitiligo was reported 
[13], whereas in two other studies, it was shown that the seroprevalence of HCV in 
vitiligo patients was not significantly different from the controls [14, 15]. In all these case 
reports, severity of the vitiligo and virological response achieved were correlated. 
Sustained virological response (SVR) due to stronger immune response was associated 
strongly with appearance of more generalized vitiligo lesions. However, a direct 
association between chronic hepatitis C and vitiligo is still debatable. 
It appears that the time of onset and the course of vitiligo in IFN-α and PEG-IFN-α-
associated cases is variable. Hamadah et al. [16] reported 8 cases of noninjection site IFN-
treatment-related vitiligo in chronic hepatitis C patients. Autoimmune disease history 
(Hashimato’s thyroiditis and primary hypothyroidism) was noted in 2 out of 8 patients 
[16]. In one case report, vitiligo vanished completely after cessation of IFN [5] while in 
others, skin lesions persisted even after a few months of withdrawal of IFN [6] or PEG-
IFN-α 2a [17].  
Interestingly, Taffaro et al. [18] reported a chronic hepatitis C patient whose old 
vitiligo lesions improved after initiation of PEG-IFN-α 2a and ribavirin therapy. It may be 
a result of immune modulation by PEG-IFN. 
Vitiligo at injection site of IFN-α 2b has been reported in one case of hepatitis C who 
was previously diagnosed with vitiligo capitis [8]. What makes these case reports unique 
is that vitiligo originated at the injection site of PEG-IFN-α 2a in patients with no past 
medical history and has diffusely progressed in one patient (table 2). 
PEG-IFN as an Etiological Factor for Vitiligo 
The suggested etiopathogenesis behind drug-induced vitiligo is: (1) activation of 
cytotoxic T cells directed against melanocyte antigens, (2) damage to sympathetic nerves 
that are connected by chemical synapses to melanocytes with a resultant functional 
disturbance, and (3) a direct cytotoxic nature of the drug on melanocytes (apoptosis). 
Most of the mechanisms suggested are hypothetical with no direct or scientific evidence 
to establish the exact role of the implicated drug. 
The mechanism of action of PEG-IFN, a well-known immune-modulator, may provide 
a clue for its role in the pathogenesis of vitiligo. Current knowledge supports the role of 
PEG-IFN-α therapy in accelerated lymphocyte attachment to endothelial cells with 
deposition of immune complexes and vasculitis [19, 20]. In our patients, we hypothesize 
that vitiligo at PEG-IFN-α 2a injection site could be due to PEG-IFN-induced cytotoxic 
T-cell-mediated immune response against melanocytes at the injection site, with a 
resultant local destruction of melanocytes. It is possible that PEG-IFN-α 2a might have 
triggered this process in chronic hepatitis C patients. Its role as a causative factor is also 
supported by similar findings in patients during the treatment of chronic myeloid 
leukemia, hepatitis B and C, and malignant melanoma [3–7].  
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Viral genotype and host immune status may explain the localization or the progression 
of vitiligo in our patients. In the patient with genotype 1a, early virologic response and 
early treatment response was achieved and maintained for a short span of time. The SVR 
was not achieved in this patient. We consider the cytokine profile in this strain of patients 
may be of the Th2 variety. Th2 cells secrete IL-4, IL-5, and IL-10, which help B cells 
produce neutralizing antibodies. The cytokines shift the body’s attack mechanism towards 
increasing the humoral response while decreasing the cytotoxic component. With the 
body’s immune response focusing on non-self targets, attack on melanocytes is 
suppressed and progression of vitiligo is prevented after treatment. 
In our second patient with genotype 2b, SVR was achieved. We consider the higher 
Th1 activity in genotype 2b is more efficient at removing virally infected cells. Th1 
produces IL-2, which encourages cytotoxic T cells to induce apoptosis in the infected 
cells, and IFN-γ, which stimulates macrophages to engulf the virally infected particle. The 
Th1 cytokines and stronger cell-mediated immune response may be the reason for a more 
intense form of vitiligo in this patient [21]. Due to its potential to reveal the future course 
of this adverse event, monitoring cytokines may be considered for research purposes. 
PEG-IFN-Related Dermatological Side Effects 
A list of dermatological side effects related to PEG-IFN has been reported which 
include necrosis, psoriasis, hyperpigmentation and vasculitis at the injection site, xerosis, 
pruritus, urticaria, and reversible hair loss, sudden onset of psoriasis or flaring of 
preexisting psoriasis, pityriasis rosea, lichen planus, eosinophilic fasciitis and vitiligo [2].  
Drugs Causing Vitiligo 
Drug-induced vitiligo is frequently reported [22–25]; some culprit drugs are listed in 
table 3. Suggested mechanisms of action in the causation of vitiligo are hypothetical. 
Vitiligo and Other Autoimmune Diseases 
Vitiligo is associated with a substantial number of other autoimmune conditions [26–
39]. In both children and adults, the most common autoimmune disorder known to be 
associated with non-segmental vitiligo is autoimmune thyroiditis [40, 41]. Skin diseases 
and malignancies have been reported in association with vitiligo [33–39]. The rare 
association of segmental subtype of vitiligo with autoimmune diseases further supports its 
neural etiology [42]. 
Conclusion 
Vitiligo with chronic hepatitis C treatment, certain other drug treatment, and its 
associated autoimmune diseases were briefly reviewed (table 4). PEG-IFN-associated 
immune modulation explained its autoimmune triggering role in our HCV and vitiligo  
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patients. Host immune status provided a clue for the localization or progression of the 
depigmentation. 
PEG-IFN-α 2a demonstrated a significant benefit in the treatment of chronic hepatitis 
C. Its antiviral benefits and adverse effects are both mediated via the induction of 
cytokines. In the era of the widespread use of PEG-IFN-α 2a as the treatment for chronic 
hepatitis C, clinicians should be aware of these diverse pigmentary changes and 
subsequent disfiguration associated with its use. Furthermore, clinicians should keep in 
mind that not all individuals treated with PEG-IFN-α 2a will experience melanocyte 
destruction. More research is indeed needed to explain the rare pathogenesis of injection 
and surrounding site vitiligo since the course of the dermatological disease is 
unpredictable. 
 
 
 
Table 1. HCV subtype and response upon treatment 
Time line  Case 1 
(Genotype 1a) 
Case 2 
(Genotype 2b) 
00 weeks  Treatment started  Treatment started 
12 weeks   VL* – undetectable  VL – undetectable 
16 weeks  Vitiligo at injection site  NA 
20 weeks  Vitiligo at injection site  Vitiligo at injection site 
24 weeks  Vitiligo at injection site 
VL – not reported 
Vitiligo at injection and surrounding site 
VL – undetectable 
48 weeks  Vitiligo at injection site 
VL – undetectable 
Vitiligo at injection and surrounding site 
VL – not reported 
06 months  Vitiligo at injection site 
VL – detectable 
More diffuse Vitiligo 
VL – undetectable 
Host immune response  Weak  Strong 
* Viral load. 
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Table 2. Case reports on PEG-IFN-α related vitiligo 
PEG-IFN  Report  Past history  
of vitiligo 
Effect of treatment 
discontinuation 
History of 
autoimmune 
disorder 
Injection site local
1 
2a 
2b 
Injection site diffuse
2 
2a 
2b 
 
Present report (case 1) 
Anbar et al., 2008 [8] 
 
Present report (case 2) 
Never reported 
 
No 
Yes 
 
No 
NA 
 
Stable 
Stable 
 
More diffuse 
NA 
 
No 
No 
 
No 
NA 
Generalized vitiligo 
2a 
 
 
 
2b 
 
Nouri et al., 1997 [43] 
Krzysztof et al., 2006 [17] 
Seckin et al., 2004 [3] 
Simsek et al., 1996 [5] 
Bernstein et al., 1995 [6] 
Patricia et al., 2006 [7] 
 
No 
Yes 
No 
No 
No 
No 
 
More diffuse 
Stable 
More diffuse 
Regression 
Stable 
Stable 
 
No 
No 
No 
No 
No 
No 
1 Local = Injection site vitiligo remained local. 
2 Diffuse = Injection site vitiligo spread to whole body. 
 
 
Table 3. Drugs causing vitiligo 
Group Drugs 
Anticonvulsants  Carbamazepine, valproic acid, clonazepam, phenytoin 
Antimalarials Chloroquine,  quinine 
Antiparkinson’s drugs  Tolcapone, levodopa 
Drugs for alopecia  Diphencyprone, squaric acid dibutylester 
Biological drugs  Interleukin-2, interleukin-4, interferon α and β, infliximab, imiqimod, imatinib
Other drugs  Fluphenazine, clofazimine, dopamine, hydroquinone monobenzylether ester, 
ganciclovir, β-blockers, lispro insulin 
 
 
Table 4. Vitiligo and other autoimmune diseases 
Associations Case  reports 
Autoimmune thyroiditis   Autoimmune hepatitis 
Autoimmune gastritis  Primary biliary cirrhosis 
Alopecia areata  Behçet’s disease 
Diabetes mellitus  Celiac disease 
Rheumatoid arthritis  Myasthenia gravis 
Pernicious anemia  Sjögren’s syndrome  
Addison’s disease  Autoimmune nephritis 
Hashimoto’s thyroiditis   Pachydermoperiostosis 
Vogt-Koyanagi-Harada Syndrome  Neurofibromatosis type 1 
Loss of hair pigmentation  Hematopoietic cell transplantation 
Polyglandular autoimmune syndrome  Dermatitis herpetiformis 
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Fig. 1. Localized vitiligo (case 1) at the injection site. a Left arm. b Right arm. 
 
 
 
Fig. 2. Generalized vitiligo (case 2) on treatment. 
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